نبذة مختصرة : ANALISIS EFEKTIFITAS BIAYA (COST EFFECTIVENESS ANALYSIS) PENGOBATAN INFEKSI SALURAN KEMIH MENGGUNAKAN ANTIBIOTIK SEFTRIAKSON DAN SIPROFLOKSASIN DI RSUP PROF. DR. R. D. KANDOURanny Inggrid Ruru1), Gayatri Citraningtyas1), Jonly P. Uneputty2)1)Program Studi Farmasi FMIPA UNSRAT Manado, 951152)Program Studi Farmasi FST Universitas Prisma Manado, 95115 ABSTRACT Urinary Tract Infection (UTI) is a condition in which germs grow and multiply in the urinary tract with a significant amount. Target therapy in UTI is infectious microorganisms by using antibiotics. The use of different antibiotics in each patient resulted in the amount of drug costs incurred by patients vary. The use of antibiotics at a relatively high cost may not necessarily guarantee the effectiveness of patient care. Therefore, a study with the aim is to determine a more cost-effective therapy between the use of antibiotics Ceftriaxone and Ciprofloxacin in patient with urinary tract infection in the Prof. Dr. R. D. Kandou Hospital, Manado. This research uses descriptive research method with retrospective data retrieval. The sample in this study consisted of 44 patient which is 22 samples of patients using Ceftriaxone and 22 samples of patients using Ciprofloxacin. The result showed, more cost-effective antibiotics in the treatment of UTI is Ceftriaxone with an ACER Rp. 503.438,33 and ICER value obtained Rp. -102.418,18 for any increase in effectiveness. Keywords: Cost Effectiveness Analysis, Urinary Tract Infection, Ceftriaxone, Ciprofloxacin.ABSTRAK Infeksi Saluran Kemih (ISK) ialah keadaan dimana kuman bertumbuh dan berkembangbiak di dalam traktus urinarius dengan jumlah yang bermakna. Sasaran terapi pada ISK adalah mikroorganisme penyebab infeksi yaitu dengan menggunakan antibiotik. Adanya penggunaan antibiotik yang berbeda pada masing-masing pasien mengakibatkan besarnya biaya obat yang dikeluarkan pasien bervariasi. Penggunaan antibiotik dengan biaya yang relatif tinggi belum tentu bisa menjamin efektifitas perawatan pasien. Oleh sebab itu, ...
No Comments.